Trials / Completed
CompletedNCT04048564
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®): A Multicentre, Ambispective Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (actual)
- Sponsor
- Incyte BioSciences France · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib. This study aims at better qualifying the ponatinib benefit-risk balance in real life and in relation with CML patients' therapeutic history.
Conditions
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2022-12-31
- Completion
- 2023-07-03
- First posted
- 2019-08-07
- Last updated
- 2023-09-28
Locations
40 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04048564. Inclusion in this directory is not an endorsement.